The odds ratios per standard deviation increase in FT3/FT4 were 10.80 for the aminotransferase-to-platelet ratio index, 4.74 for the NAFLD fibrosis score, and 3.21 for the fibrosis-4 index. "Reduced ...

Conclusions: Insulin resistance and its co-morbidities are often present in patients with NAFLD. An easily calculated score based on readily available clinical data can reliably exclude the presence ...

Correspondence to Professor Rohit Loomba, NAFLD Research Center, Division of Gastroenterology and Hepatology, Department of Medicine, University of California San Diego, La Jolla, California, USA; ...

MAFLD/NAFLD have shared and predominate causes from nutrition overload to persistent liver damage and eventually lead to the development of liver fibrosis and cirrhosis. Unfortunately, there is an ...

About 25% of NAFLD patients progress to a more severe stage including liver inflammation (nonalcoholic steatohepatitis, NASH) and scarring (liver fibrosis), which can lead to cirrhosis or even ...

About 25% of NAFLD patients progress to a more severe stage including liver inflammation (nonalcoholic steatohepatitis, NASH) and scarring (liver fibrosis), which can lead to cirrhosis or even ...

This section is a high-scoring area that tests your ability to analyze numerical data quickly. A strong performance here can significantly boost your overall score. You’ll face Data Interpretation (DI ...

Summary and Conclusion Non-alcoholic fatty liver disease (NAFLD) generally progresses through five main stages: steatosis, steatohepatitis, liver fibrosis, cirrhosis, and liver failure.

The natural history of metabolic dysfunction-associated steatotic liver disease (MASLD), previously referred to as non-alcoholic fatty liver disease (NAFLD), is complex and long. A minority of ...

It can progress from simple hepatic steatosis (MAFL) to more severe conditions like Metabolic-Associated Steatohepatitis (MASH), fibrosis, cirrhosis, and Hepatocellular Carcinoma (HCC). There is a ...